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OBJECTIVE: We sought to ascertain predictors of Patient Prosthesis Mismatch, an independent predictor of
mortality, in patients with aortic stenosis using bioprosthetic valves.
METHOD: We analyzed 2,107 sequential surgeries. Patient Prosthesis Mismatch was calculated using the effective
orifice area of the prosthesis divided by the patient’s body surface area. We defined nonsignificant, moderate, and
severe Patient Prosthesis Mismatch as effective orifice area indexes of .0.85 cm
2/m, 0.85-0.66 cm
2/m
2, and
#0.65 cm
2/m
2, respectively.
RESULTS: A total of 311 bioprosthetic patients were identified. The incidence of nonsignificant, moderate, and
severe Patient Prosthesis Mismatch was 41%, 42, and 16%, respectively. Severe Patient Prosthesis Mismatch was
significantly more prevalent in females (82%). In severe Patient Prosthesis Mismatch, the perfusion and the cross-
clamp times were considerably lower when compared with nonsignificant Patient Prosthesis Mismatch and
moderate Patient Prosthesis Mismatch. Patients with severe Patient Prosthesis Mismatch had a significantly higher
likelihood of spending time in the intensive care unit and a significantly longer length of stay in the hospital. Body
surface area was not different in severe Patient Prosthesis Mismatch when compared with nonsignificant Patient
Prosthesis Mismatch. In-hospital mortality in patients with nonsignificant, moderate, and severe Patient Prosthesis
Mismatch was 2.3%, 6.1%, and 8%, respectively. Minimally invasive surgery was significantly associated with
moderate Patient Prosthesis Mismatch in 49% of the patients, but not with severe Patient Prosthesis Mismatch.
CONCLUSION: Severe Patient Prosthesis Mismatch is more common in females, but not in those with minimal
available body surface area. Though operative times were shorter in these patients, intensive care unit and hospital
lengths of stay were longer. Surgeons and cardiologists should be cognizant of these clinical predictors and
complications prior to valve surgery.
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INTRODUCTION
Aortic valve stenosis affects 2% to 4% of older adults and
is the most common reason for valve surgery. An estimated
50,000 aortic valve procedures are performed each year in
the United States (1). However, once the aortic valve is
replaced, issues related to prosthesis-patient mismatch
(PPM) may emerge.
PPM was first described by Rahimtoola in 1978 (2). PPM
is considered to be present when the prosthetic valve used
in the patient is smaller than the normal native valve. As a
consequence of the smaller prosthetic valve, the left
ventricle has to produce higher pressures to overcome
the mechanical resistance produced by the new device.
This is transmitted in higher transvalvular pressure
gradients as measured by Doppler (2). It has been
demonstrated that the high-pressure gradients through
the prosthesis are associated with higher morbidity and
impact both short- and long-term mortality, when com-
pared with prostheses of adequate size, based on the
patient’s body surface area (4-5).
It has been shown that PPM is a common problem in
patients undergoing AVR, occurring in up to 70% of aortic
valve replacements (3). At the same time, this problem can
be prevented through the use of a systematic approach prior
to surgery (3). This may result in enhanced recovery with
lower morbidity and mortality. The aim of this study was to
determine the prevalence, clinical predictors, and short-
term impact of severe PPM.
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55METHODS
Patient population: After obtaining approval from the
independent review board, we retrospectively reviewed
2,107 consecutive heart surgeries performed at ourinstitution
between January 2005 and June 2009. Of these, 964 were
coronary artery bypass surgeries, 683 involved single-valve
surgeries, 411 were concomitant valve and bypass surgeries,
and 144 were multivalve surgeries. From this group, patients
with a diagnosis of severe aortic stenosis (AVA#1c m
2) were
included in the study, along with those in whom a
bioprosthetic valve was used for the aortic valve replace-
ment. Patients with concomitant valve or coronary artery
bypass surgery were also included in the study, but patients
with a diagnosis of aortic insufficiency as the reason for AVR
were excluded.Baseline preoperativeandoperativevariables
were used based on the information provided by the Society
of Thoracic Surgeons database in Tables 1 and 2.
Measurements: The effective orifice area (EOA) of each
valve was obtained from a list that the American Society of
Echocardiography published in their 2009 Recommenda-
tions for the Evaluation of Prosthetic Valves with
Echocardiography and Doppler Ultrasound (6), which was
based on a published report of normally functioning aortic
valve prostheses (7). The effective orifice area values
obtained from in vivo measurements for the different
bioprosthetic aortic valves used during this analysis are
given in Table 3. PPM was calculated using the EOA of the
aortic valve prosthesis, which was divided by the patient’s
body surface area to obtain the indexed EOA. We defined
nonsignificant, moderate, and severe PPM as an indexed
EOA of .0.85 cm
2/m
2, 0.66 cm
2/m
2 to #0.85 cm
2/m
2, and
#0.65 cm
2/m
2, respectively (12). We defined the nonsigni-
ficant PPM group as our control because they received the
optimal therapy. Mortality was analyzed at the time of
discharge from the hospital.
Statistical Analysis: Continuous variables are expressed
as the mean ¡1 SD; comparisons were conducted by t-
tests/ANOVAs or nonparametric Mann-Whitney/Kruskal-
Wallis tests if the normality assumption was violated when
comparing severe PPM with no PPM or severe PPM with
moderate PPM. Discrete variables are presented as percen-
tages and relatives frequencies; comparisons were con-
ducted by chi-squared statistics or Fisher’s exact test, as
appropriate. A p-value ,0.05 was considered statistically
significant. A stepwise logistic regression analysis (back-
ward Wald) was used for the variables with a p-value ,0.05
to assess the independent predictors of PPM and length of
stay in the intensive care unit. We used a software system
(Statistical Package for the Social Sciences, SPSS version 17
Chicago, Illinois) for all analyses.
RESULTS
A total of 311 patients (128 females and 183 males) with a
diagnosis of severe aortic stenosis who underwent AVR
with a bioprosthetic valve were identified. Based on the
severity of the PPM, the cohort was divided in three groups:
non-significant PPM (n=129), 41%; moderate PPM (n=132),
42%; and severe PPM, (n=50) 16%. PPM was present in 58%
of the total population, in 42% as moderate PPM and in 16%
as severe PPM.
Patient characteristics: The baseline characteristics are
presented in Table 1. The mean age was 75¡11, 73¡9, and
77¡7 years for nonsignificant, moderate, and severe PPM,
respectively (p=0.6). Females represented 82% of the severe
PPM group compared with 34% and 32% of the nonsigni-
ficant and moderate PPM groups, respectively (p,0.001)
(Figure 1). There was no discrepancy in age between the
different groups of PPM, (p=0.6). The body surface area
was lowest in the severe PPM group (1.75¡0.5 m
2)
compared with 1.97¡0.2 m
2 of the moderate PPM
Table 1 - Preoperative Data.
Patients
Non PPM
n=129 (41%)
Moderate PPM
n=132 (42%)
Severe
PPM n=50(16%) p-value
Age (years) 75¡11 73¡97 7 ¡7 0.6
Female 45 (34.9%) 42 (32.1%) 41 (82%) ,0.001
Body surface area (m
2) 1.80¡0.2 1.97¡0.2 1.75¡0.25 0.155*
Body mass index (Kg/m
2) 26.6¡4.27 29.4¡5.4 27.8¡6.2 0.120*
NYHA class $ III 49 (38%) 49 (37%) 28 (56%) 0.05
Diabetes mellitus 34 (26%) 59 (44%) 17 (34%) 0.008
Renal failure 3 (2.3%) 4 (3%) 6 (12%) 0.01
Hypertension 111 (86%) 125 (95%) 47 (94%) 0.04
Cerebrovascular disease 12 (9.3%) 10 (7.6%) 6 (12%) 0.64
Smoker 33 (25%) 37 (28%) 17 (34%) 0.53
Chronic lung disease 79 (61%) 86 (65%) 34 (68%) 0.65
Peripheral vascular disease 14 (11%) 7 (5.3%) 4 (8%) 0.25
Prior coronary artery bypass grafting 11 (8.5%) 16 (12%) 6 (12%) 0.60
Myocardial infarction 11 (8.5%) 16 (12%) 10 (20%) 0.10
Left ventricular ejection fraction #55% 45 (35%) 47 (36%) 14 (28%) 0.60
Mean ejection fraction 52¡12 52¡13 54¡12 0.62
Preoperative aortic valve gradient (mmHg) 53¡19 53¡22 51¡18 0.38
Severe mitral insufficiency 13 (10%) 18 (14%) 14 (28%) 0.009
Preoperative Medical Therapy
Beta-blockers
74 (57%) 85 (64%) 30 (60%) 0.50
Angiotensin converting enzyme inhibitors 43 (33%) 59 (45%) 15 (30%) 0.08
Aspirin 46 (36%) 55 (42%) 19 (38%) 0.60
Lipid lowering medications 66 (51%) 75 (57%) 32 (64%) 0.30
*represents the p-value of severe PPM vs. no PPM.
NYHA: New York Heart Association heart failure class.
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56(p,0.001), but this was not significantly different when
compared with the nonsignificant PPM group value of
1.80¡0.2 m
2 (p=0.155).
Body mass index did not differ between the severe
(27.8¡6.2 Kg/m
2) and moderate groups (29.4¡5.4 Kg/m
2),
(p=0.10), or when comparing nonsignificant (26.6¡4.27 Kg/
m
2) and severe mismatch groups, (p=0.12).Advancedheart
failure (based on the New York Heart Association criteria)
was found in 56% of patients in the severe group (p=0.05).
Diabetes mellitus was more prevalent in patients with
moderate PPM (p=0.008). Hypertension was prevalent in all
ofthegroups,in particular,inthosewithmoderateandsevere
mismatch (p=0.04). Renal failure (serum creatinine .2m g /
dl) was higher in the severe PPM group, (p=0.01). Coronary
artery disease, with previous coronary artery bypass grafting
(CABG) was similar in all groups as well, (p=0.6).
The echocardiographic basal characteristics of the study
population presented no differences in the mean ejection
fraction: no PPM, 52¡12%; moderate PPM, 52¡13%; and
severe PPM, 54¡12%, (p=0.62). Likewise, the aortic valve
gradient was not significantly different: 53¡19 mmHg,
53¡22 mmHg, and 51¡18 mmHg, in that order, (p=0.38).
Surgical data: Most of the procedures were elective.
Coronary artery bypass graft surgery was performed in 41%
(nonsignificant PPM), 36% (moderate PPM), and 42%
(severe PPM), respectively, (p=0.67). Concomitant mitral
valve surgery was performed in 34% of the severe PPM
group, 17% of the moderate PPM group, and 12% in the no-
PPM group (p=0.003). Tricuspid valve surgery was com-
pleted in 8% of the severe PPM cases. A total of six (6) aortic
annular enlargement procedures was performed; two in the
no PPM, one in the moderate PPM, and three in the severe
PPM groups.
Interestingly, the operative data in Table 2 show that
patients in the severe PPM group had the shortest perfusion
(p=0.009) and cross-clamp times (p=0.005) (Figure 2).
However, the same group had the highest total intensive
care unit length of stay with a mean value of 203 hours
compared with 146 and 130 hours in the nonsignificant and
moderate PPM groups, respectively (Figure 3). This was
statistically significant (p=0.012) when comparing severe
and moderate PPM. No other factors were associated with
the amount of intensive care unit hours except for the PPM
difference. However, there was a statistical trend (p=0.08)
for prolonged mechanical ventilation in hours in the severe
mismatch group (Figure 4). Along with these findings,
patients with severe mismatch had the longest hospital stay
with a mean value of 20 days compared with 15 and 14 days
Table 2 - Operative Data.
Variables Non PPM n=129 (41%) Moderate PPM n=132 (42%) Severe PPM n=50 (16%) p-value
Elective 129 (100%) 129 (98%) 50 (100%) 0.12
Coronary artery bypass grafting 53 (41%) 48 (36%) 21 (42%) 0.67
Left main disease 4 (3.1%) 8 (6.0%) 4 (8%) 0.34
Mitral valve surgery 16 (12%) 23 (17%) 17 (34%) 0.003
Tricuspid valve surgery 0 1 (0.8%) 4 (8%) 0.01
Aortic annular enlargement 2 (1.6%) 1 (0.8%) 3 (6%) 0.06
Intra-aortic balloon pump use 19 (15%) 27 (20%) 13 (26%) 0.19
Intraoperative blood use 68 (52.7%) 78 (59.1%) 28 (56%) 0.58
Perfusion time (minutes) 118¡38 114¡40 100¡42 0.009
1
Cross-clamp time (minutes) 87.2¡32 83.3¡33 72.2¡28 0.005
2
Minimally invasive surgery 38 (32%) 37 (28%) 0 ,0.001
Complications
Total intensive care unit length of stay (hours) 146¡339 130¡137 203¡250 0.012
3
Prolonged ventilation (hours) 73¡268 48¡100 112¡304 0.08
Permanent neurologic complications 5 (3.9%) 3 (2.3%) 2 (4%) 0.72
Transient neurologic complications 0 1 (0.8%) 1 (2%) 0.31
Pneumonia 10 (7.8%) 6 (4.5%) 3 (6%) 0.13
Renal failure 10 (7.8%) 10 (7.6%) 5 (10%) 0.9
Short-term mortality 3 (2.3%) 8 (6.1%) 4 (8%) 0.19
Length of hospital stay (days) 15¡16 14¡10 20¡13 0.04
1p-value between severe PPM versus no PPM. p=0.05 between severe PPM versus moderate PPM.
2p-value between severe PPM versus no PPM. p=0.04 between severe PPM vs. moderate PPM.
3p-value between severe PPM versus moderate PPM. p=0.27 between severe PPM and no PPM.
Table 3 - Reference values of effective orifice area for bioprosthetic aortic valves.
Size, mm Prosthetic Valve
19 21 23 25 27 29
No. of Patients 54 98 90 51 17 1
Mosaic Porcine 121 1.4 1.5 1.8 1.9 2.1
Freestyle 4 1.4 1.7 2.1 2.5
Mitroflow 1 1.1 1.3 1.5 1.8
Carpentier Edwards Standard 166 0.9 1.5 1.7 1.9 2.3 2.8
stented porcine
Carpentier Edwards Pericardial 19 1.2 1.5 1.8
stented bovine pericardial
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57in the nonsignificant and moderate PPM groups, respec-
tively (p=0.04) (Figure 5). Fifteen cases of in-hospital
mortality were identified, three in nonsignificant PPM,
eight in moderate PPM, and four in the severe PPM groups
(p=0.19). Seventy-five minimally invasive surgeries were
performed, 38 (50%) had nonsignificant PPM and 37 (50%)
had moderate PPM. No case of severe PPM was found to be
associated with minimally invasive surgery.
Table 3 shows the different types of bioprosthetic valves
used. The Carpentier Edwards Standard (Edwards Life-
sciences, Irvine, CA), and the Mosaic Porcine (Medtronic,
Minneapolis, MN) were the most commonly used, 53% and
39% of the time, respectively. A valve size of 21 mm was
implanted in 31% of the surgeries, making it the most
frequently used, while a valve size of 23 mm was the second
most common, being used 29% of the time.
Independent Risk Factors: Univariate analysis from
preoperative data showed that female gender and renal
failure were statistically associated with severe PPM.
Diabetes mellitus and ACE inhibitors use were associated
with the moderate PPM group but not with the severe PPM
group. Further multivariable analysis demonstrated that
female gender was associated with severe mismatch
(p,0.001), even when compared with the nonsignificant as
well as the moderate PPM groups.
DISCUSSION
In patients undergoing AVR, PPM is a commonly
encountered problem that leads to worsened hemodynamic
function, less regression of left ventricular hypertrophy, and
more cardiac events with lower survival rates (4,11,12).
Other studies have demonstrated an association between
female gender and higher operative mortality after valvular
heart surgery (15).
Our results indicate that female gender is an indepen-
dent risk factor for severe prosthesis-patient mismatch.
This association was observed after the body surface area
of the severe mismatch group proved not to be significantly
different when compared with the group without any
mismatch. When compared with men, women in general
have a smaller body surface area and a smaller aortic
annulus. Accordingly, PPM has proven to be more
common in older females with concomitant coronary artery
disease (16-18).
Our study demonstrated that 82 percent of severe
mismatches corresponded to females without differences
in age or any other baseline characteristics. Interestingly,
this particular group had the shortest operative times. It is
our impression that the use of smaller prosthetic valves for
small and severely calcified annuli may have shortened the
Figure 1 - Percentage of prosthesis-patient mismatch by gender.
Figure 2 - Total amount of intensive care unit hours distributed
according to patient-prosthesis mismatch.
Figure 3 - Hours of mechanical ventilation according to the
severity of patient-prosthesis mismatch.
Figure 4 - Total amount of mechanical ventilation in hours
distributed according to patient-prosthesis mismatch.
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58surgical times. It is possible that the reason is associated
with the fact that surgeons did not have to enlarge the aortic
root. PPM is therefore more frequently encountered in
females, and the discrepancy between the inadequate size of
both the prosthesis and the patient have proven to be risk
factors for mortality (4,12,13). At the same time, the female
heart responds differently than the male heart does for the
same degree of left ventricular outflow obstruction, result-
ing in smaller end-systolic chamber size and higher
pressures in the female heart response (18). This is
particularly common with elderly patients with an excessive
or inappropriate degree of hypertrophy; wall thickness is
greater than necessary to counterbalance the high intraca-
vitary pressures. As a result, the systolic wall stress is lower,
and the ejection fraction is higher; such inappropriate LV
hypertrophy has been associated with higher perioperative
morbidity and mortality (17-19).
We found a significant impact of severe PPM on the
intensive care unit length of stay and on the total hospital
length of stay. Because of the nature of the study, we cannot
establish a causal relationship between the degree of PPM
and the findings. However, it has been demonstrated that
abnormal intracavitary flow accelerations (defined as the
presence of a dagger-shaped intracavitary flow signal on
continuous-wave Doppler) after aortic valve replacement
for severe aortic stenosis are associated with concentric left
ventricular hypertrophy and supernormal systolic function.
The abnormal intracavitary flow acceleration and concentric
left ventricular hypertrophy were associated with higher in-
hospital mortality, morbidity and prolonged intubation (17-
20). Although not directly investigated in our study, this
may have played a role in our patients.
We demonstrated that minimally invasive surgery may be
related to a higher frequency of moderate PPM, but also to a
lower rate of severe PPM; we believe that if this is
confirmed, it is likely to have clinical implications with
respect to the selection of a particular surgical technique.
For this reason, we are currently prospectively exploring
this possibility in our institution.
This study highlights the importance of avoiding PPM,
particularly in females who react differently from a
pathophysiologic standpoint. Aortic PPM can be avoided
through optimal prosthesis selection in the individual
patient by calculating the necessary indexed EOA prior to
surgery (3). This is particularly important in patients with
left ventricular dysfunction and/or severe left ventricular
hypertrophy (3).
Study Limitations: The current study was based on data
obtainedfromapatientregistrywithretrospectiveanalysisand
was not able to establish a causal relationship. The post-
operative intracavitary flow accelerations were not available
but may have helped to confirm our hypothesis. The assess-
ment of these parameters along with the patient’s outcome
may have an impact on selecting the appropriate therapy.
AUTHOR CONTRIBUTIONS
Lamelas GA and Lamas J coordinated the study. Urbandt PA and Santana
O wrote and reviewed the article. Astudillo LM and Nascimento FO
collected the data. Benjo AM performed the statistical analysis. Elkayam
LU performed the statistical analysis and reviewed the manuscript.
REFERENCES
1. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease.
Pathogenesis, disease progression, and treatment strategies. Circulation
2005;111:3316-26.
2. Rahimtoola SH. The problem of valve prosthesis-patient mismatch.
Circulation 1978;58:20-4.
3. Pibarot P, Dumesnil JG. Prosthetic Heart Valves. Selection of the optimal
prosthesis and long-term management. Circulation 2009;119:1034-48.
4. Blais C, Dumesnil JG, Baillot R, Simard S, Doyle D, Pibarot P. Impact of
valve prosthesis-patient mismatch on short-term mortality after aortic
valve replacement. Circulation. 2003;108:983-8.
5. Mohty D, Malouf JF, Girard SE, Schaff HV, Grill DE, Enriquez-Sarano
ME, et al. Impact of prosthesis-patient mismatch on long-term survival in
patients with small St. Jude medical mechanical prosthesis in the aortic
position. Circulation. 2006;113:420-6.
6. Zoghbi WA, Chambers JB, Dumesnil JG, Foster E, Gottdiener JS, Grayburn
PA, et al. Recommendations for evaluation of prosthetic valves with
echocardiography and doppler ultrasound: a report From the American
Society of Echocardiography’s Guidelines and Standards Committee and
the Task Force on Prosthetic Valves, developed in conjunction with the
American College of Cardiology Cardiovascular Imaging Committee,
Cardiac Imaging Committee of the American Heart Association, the
European Association of Echocardiography, a registered branch of the
European Society of Cardiology, the Japanese Society of Echocardiography
and the Canadian Society of Echocardiography, endorsed by the American
College of Cardiology Foundation, American Heart Association, European
Assocation of Echocardiography, a registered branch of the European
Society of Cardiology, the Japanese Society of Echocardiography, and
Canadian Society of Echocardiography. J Am Soc Echo. 2009;22:975-1014.
7. Rajani R, Mukherjee D, Chambers JB. Doppler echocardiography in
normally functioning replacement aortic valves: a review of 129 studies.
J Heart Valve Dis. 2007;16:521-35.
8. Oakley RE, Kleine P, Bach DS. Choice of prosthetic heart valve in today’s
practice. Circulation. 2008;117:253-6.
9. Pibarot P, Dumesnil JG. Hemodynamic and clinical impact of prosthesis
patient mismatch in the aortic valve position and its prevention. J Am
Coll Cardiol. 2000;36:1131-41.
10. Rahimtoola SH. Choice of prosthetic heart valve for adult patients. J Am
Coll Cardiol. 2003;41:893-904.
11. Rubio Alvarez J, Sierra Quiroga J, Vega Fernandez M, Adrio Nazar B,
Gude Sampedro F, Martinez Comendador JM, et al. Up to twenty-five-
year survival after aortic valve replacement with size 19 mm valves.
Inter Cardiovasc and Thorac Surg. 2010;10:32-6.
12. Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: definition, clinical
impact, and prevention. Heart. 2006;92:1022-9.
13. Walther T, Rastan A, Falk V, Lehmann S, Garbade J, Funkat AK, et al.
Patient prosthesis mismatch affects short and long term outcomes after
aortic valve replacement. Eur J Cardiothorac Surg. 2006;30:15-9.
14. Pai RG, Kapoor N, Bansal RC, Varadarajan P. Malignant natural history
of asymptomatic severe aortic stenosis: benefit of aortic valve replace-
ment. Ann Thorac Surg. 2006;82:2116-22.
15. Edwards FH, Peterson ED, Coombs LP, DeLong ER, Jamieson WR,
Shroyer ALW, et al. Prediction of operative mortality after valve
replacement surgery. J Am Coll Cardiol. 2001;37:885-92.
16. Taggart DP. Prosthesis patient mismatch in aortic valve replacement:
possible but pertinent? Eur Heart J. 2006;27:644-6.
17. Aurigemma G, Battista S, Orsinelli D, Sweeney A, Pape L, Cuenoud H.
Abnormal left ventricular intracavitary flow acceleration in patients
undergoing aortic valve replacement for aortic stenosis: a marker for
high postoperative morbidity and mortality. Circulation. 1992;86:926-36.
Figure 5 - Total length of in-hospital stay in days distributed
according to patient-prosthesis mismatch.
CLINICS 2012;67(1):55-60 PPM mismatch predictors after AVR
Astudillo LM et al.
5918. Carroll JD, Carroll EP, Feldman T, Ward DM, Lang RM, McGaughey D,
et al. Sex-associated differences in left ventricular function in aortic
stenosis of the elderly. Circulation. 1992;86:1099-107.
19. Orsinelli DA, Aurigemma GP, Battista S, Krendel S, Gaasch WH. Left
ventricular hypertrophy and mortality after aortic valve replacement for
aortic stenosis: a high risk subgroup identified by preoperative relative
wall thickness. J Am Coll Cardiol. 1993;22:1679-83.
20. Duncan AI, Lowe BS, Garcia MJ, Xu M, Gillinov AM, Mihaljevic T, et al.
Influence of concentric left ventricular remodeling on early mortality
after aortic valve replacement. Ann Thorac Surg. 2008;85:2030-9.
PPM mismatch predictors after AVR
Astudillo LM et al.
CLINICS 2012;67(1):55-60
60